Skip to main content
SpringerLink
Log in

A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response

  • Case Report - Surgery
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Here, we present a patient with hepatocellular carcinoma complicated by tumor thrombosis into the main portal trunk and perihepatic lymph node metastases who was treated with atezolizumab plus bevacizumab. Shrinkage of the main tumor, portal vein thrombosis, and lymph node metastases were achieved; therefore, hepatectomy with lymphadenectomy could be performed. Final pathology indicated a complete pathological response in the main tumor, portal vein thrombosis, and perihepatic lymph nodes. The patient is currently alive with no evidence of recurrence on radiological assessment at 3 months after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The dataset generated and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  PubMed  Google Scholar 

  2. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681–693

    Article  PubMed  Google Scholar 

  3. Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S et al (2023) Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res 53(5):383–390

    Article  PubMed  Google Scholar 

  4. Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A et al (2016) Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 3:41–53

    Article  PubMed  PubMed Central  Google Scholar 

  5. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905

    Article  CAS  PubMed  Google Scholar 

  6. Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J et al (2022) Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol 40(4_suppl):379

  7. Okuno M, Ishii T, Ichida A, Soyama A, Takemura N, Hirono S et al (2023) Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab. BMC Cancer 23(1):780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Japan LCSGo (2010) General rules for the clinical and pathological study of primary liver cancer, 3 edn. Kanehara & Co., Ltd., Tokyo

  9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

  10. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60

    Article  CAS  PubMed  Google Scholar 

  11. Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M et al (2018) Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 48(6):442–450

    Article  CAS  PubMed  Google Scholar 

  12. Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H et al (2023) Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer 12(4):321–338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hoshino T, Naganuma A, Furusawa A, Suzuki Y, Hirai K, Sakamoto I et al (2022) A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. Clin J Gastroenterol 15(4):776–783

    Article  PubMed  Google Scholar 

  14. Kurisaki K, Soyama A, Hara T, Matsushima H, Imamura H, Tanaka T et al (2023) Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg 40(1–2):84–89

    Article  CAS  PubMed  Google Scholar 

  15. Fukunaga A, Takata K, Itoh S, Yamauchi R, Tanaka T, Yokoyama K et al (2023) Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol 16(2):224–228

    Article  PubMed  Google Scholar 

  16. Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D et al (2023) Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res 43(2):943–947

    Article  PubMed  Google Scholar 

  17. Shindoh J, Kawamura Y, Kobayashi Y, Kobayashi M, Akuta N, Okubo S et al (2021) prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol 28(12):7663–7672

    Article  PubMed  Google Scholar 

  18. Okuno M, Hatano E, Tada M, Nishimura T, Okamoto T, Sueoka H et al (2024) Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma. Anticancer Res 44(4):1727–1737

    Article  PubMed  Google Scholar 

  19. Lee BM, Choi JY, Seong J (2023) Efficacy of local treatment in lymph node metastasis from hepatocellular carcinoma. Liver Cancer 12(3):218–228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Elsholtz FHJ, Asbach P, Haas M, Becker M, Beets-Tan RGH, Thoeny HC et al (2021) Introducing the node reporting and data system 1.0 (node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur Radiol 31(8):6116–6124

Download references

Funding

This study was partly supported by JSPS KAKENHI (grant number 21K16486).

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan

    Masayuki Okuno, Ikuo Nakamura, Daisuke Shirai, Takahito Hirai, Hiroaki Fuji, Ami Kurimoto, Tomohiro Okamoto, Hideaki Sueoka, Kenjiro Iida, Masaharu Tada & Seiko Hirono

  2. Department of Surgery, Hanwa Memorial Hospital, Osaka, Japan

    Masayuki Okuno

  3. Department of Gastroenterology, Takarazuka City Hospital, Takarazuka, Japan

    Hideko Ohama & Hironori Tanaka

  4. Department of Surgical Pathology, Hyogo Medical University, Nishinomiya, Japan

    Makoto Yoshida & Takako Kihara

Authors
  1. Masayuki Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideko Ohama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ikuo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Shirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahito Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroaki Fuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ami Kurimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomohiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideaki Sueoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kenjiro Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masaharu Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Takako Kihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hironori Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Seiko Hirono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Okuno.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

Informed consent was obtained from the individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okuno, M., Ohama, H., Nakamura, I. et al. A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response. Int Canc Conf J (2024). https://doi.org/10.1007/s13691-024-00683-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13691-024-00683-5

Keywords

Search

Navigation